

UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. A Component Unit of the University of Louisville For the Years Ended June 30, 2023 and 2022

Table of Contents:

	Page
Independent Auditor's Report	. 1
Management's Discussion and Analysis (Unaudited)	. 4
Basic Financial Statements	
Statements of Net Position	. 14
Statements of Revenues, Expenses, and Changes in Net Position	. 15
Statements of Cash Flows	. 17
Notes to Financial Statements	. 19
Required Supplementary Information (Unaudited)	. 33



INDEPENDENT AUDITORS' REPORT

Board of Directors University of Louisville Research Foundation, Inc. Louisville, Kentucky

Report on the Audit of the Financial Statements Opinion

We have audited the accompanying financial statements of University of Louisville Research Foundation, Inc. (Research Foundation), a component unit of the University of Louisville, as of and for the years ended June 30, 2023 and 2022, and the related notes to the financial statements, which collectively comprise the Research Foundation's basic financial statements as listed in the table of contents.

In our opinion, the financial statements referred to above present fairly, in all material respects, the respective financial position of the Research Foundation, as of June 30, 2023 and 2022, and the respective changes in financial position, and, where applicable, cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Research Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Research Foundation's ability to continue as a going concern for twelve months beyond the financial statement date, including any currently known information that may raise substantial doubt shortly thereafter.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due
 to fraud or error, and design and perform audit procedures responsive to those risks. Such
 procedures include examining, on a test basis, evidence regarding the amounts and disclosures
 in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of Research Foundation's internal control. Accordingly, no such
 opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Research Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Board of Directors University of Louisville Research Foundation, Inc.

Required Supplementary Information

Accounting principles generally accepted in the United States of America require that the Management's Discussion and Analysis on pages 4 through 13, and the Post-employment Benefit Information on page 33 be presented to supplement the basic financial statements. Such information is the responsibility of management and, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with GAAS, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audits of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

CliftonLarsonAllen LLP

Clifton Larson Allen LLP

St. Louis, Missouri October 23, 2023

Introduction

The following discussion and analysis provides an overview of the financial position and activities of the University of Louisville Research Foundation, Inc. (Research Foundation) for the years ended June 30, 2023 and 2022. Comparative information for the year ended June 30, 2021 has been provided where applicable. This discussion has been prepared by management and should be read in conjunction with the financial statements and the notes thereto, which follow this section.

The Research Foundation is a nonprofit corporation affiliated with the University of Louisville (University), a state-supported metropolitan research university located in Louisville, Kentucky. The Research Foundation was established in 1989 for the purpose of promoting and supporting research projects, investigations, and other activities relating to the educational, scientific, literary, artistic, health care and public service missions of the University.

The University's strategic plan guides the Research Foundation's programs, along with the grand challenges from the Kentucky Council on Postsecondary Education: 1) empowering our communities, 2) advancing our health, and 3) engineering our future economy by focusing on our research on our community to foster equity and eliminate gaps in health, education and economic attainment. The Research Foundation accepts funding for research, training, and service from extramural sources for programs and projects that match these goals. During the fiscal year ended June 30, 2023, total awards were \$175.9 million. Some of the funding highlights include:

- Awards from the National Institute of health (NIH) accounting for over \$79 million of the awards received during the current fiscal year, including \$3.6 million for IDEA Networks for Biomedical Research Excellence in Kentucky and \$2.3 million for functional macrobiotics, inflammation and pathogenicity.
- An award from the Kentucky Cabinet for Health and Family Services for \$3.4 million for research
 of the health equity initiatives.

Using the Financial Statements

The Research Foundation's financial report includes the statements of net position; the Statements of revenues, expenses, and changes in net position; and the statements of cash flows. These financial statements are prepared in accordance with Government Accounting Standards Board (GASB) principles, which establish standards for external financial reporting for public colleges and universities. The Research Foundation is presented here as a single entity and is also included in the consolidated financial statements of the University.

Statements of Net Position

The statements of net position present the financial position of the Research Foundation at the end of the fiscal year and include all assets, deferred outflows of resources, liabilities and deferred inflows of resources. Net position (the difference between assets, liabilities, deferred outflows of resources and deferred inflows of resources) provides a snapshot of the current financial condition of the Research Foundation at the end of a fiscal year. Items on the statements of net position are generally measured using current values with the exception of capital assets which are stated at historical cost less accumulated depreciation. The change in net position indicates whether the Research Foundation accumulated or consumed resources during the year.

A condensed version of the Research Foundation's assets, liabilities, and net position at June 30, 2023, 2022, and 2021 (in thousands) is summarized below:

	2023	2022	2021 (Restated)		2023-2022 Change)22-2021 Change
ASSETS AND DEFERRED OUTFLOWS OF RESOURCES							
Current assets	\$ 258,678	\$ 208,829	\$	169,702	\$	49,849	\$ 39,127
Capital assets	58,102	51,475		54,193		6,627	(2,718)
Right-to-use asset, net	3,050	5,035		5,272		(1,985)	(237)
Other noncurrent assets	657,424	680,915		678,488		(23,491)	2,427
Deferred outflow of resources	6,450	5,964		5,438		486	526
TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES	983,704	952,218		913,093		31,486	39,125
LIABILITIES AND DEFERRED INFLOWS OF RESOURCES							
Current liabilities	54,014	46,369		35,203		7,645	11,166
Noncurrent liabilities	35,202	38,035		34,423		(2,833)	3,612
Deferred inflows of resources	644,204	659,534		678,901		(15,330)	(19,367)
TOTAL LIABILITIES AND DEFERRED INFLOWS OF RESOURCES	733,420	743,938		748,527		(10,518)	(4,589)
NET POSITION							
Net investment in capital assets	59,149	51,519		54,347		7,630	(2,828)
Restricted - expendable	22,320	24,422		17,536		(2,102)	6,886
Unrestricted	168,815	132,339		92,683		36,476	39,656
TOTAL NET POSITION	250,284	208,280		164,566		42,004	43,714
TOTAL LIABILITIES, DEFERRED INFLOWS OF RESOURCES AND NET POSITION	\$ 983,704	\$ 952,218	\$	913,093	\$	31,486	\$ 39,125

Assets

Current assets of \$258.7 million consist of \$137.4 million in cash and cash equivalents, \$99.0 million of accounts receivable and \$21.4 million due from affiliate. The Research Foundation's cash and cash equivalents grew \$30.6 million from the previous year due to the results of contracted activities with hospitals and cost reduction measures. Accounts receivable increased \$17.5 million mostly representing an increase in outstanding patient receivable balances. The due from affiliates decrease of \$21.9 million stems from collections of payments due and a reduction of approximately \$15.0 million in the fiscal year 2022 profit share from UL Health as compared to the fiscal year 2021 profit share.

Noncurrent assets of \$718.6 million consist mainly of long-term receivables of \$642.9 million, which \$642.1 million relates to future lease payments receivable for the contracted use of University or Research Foundation assets. Additionally, noncurrent assets includes \$58.1 million of capital assets, which increased by \$6.6 million due to asset purchases, net depreciation.

Deferred Outflows of Resources

Deferred outflow of resources represents a consumption of net assets applicable to a future period. The balance of \$6.4 million as of June 30, 2023 consisted of future payments to be made for other post-employment benefits.

Liabilities

The Research Foundation's current liabilities of \$54.0 million consist \$3.7 million of unearned grant revenue for sponsored research activities, a decrease of \$0.7 million compared to June 30, 2022. The Research Foundation is required to set up a liability when awards are paid in advance, as they are responsible for paying back any unused funds to the sponsor. Current liabilities also consists of \$38.0 million related to trade accounts payable and other accrued liabilities.

The Research Foundation's allocated portion of other post-employment benefits totals \$27.8 million, shown as other long-term liabilities, which decreased by \$3.1 million due primarily to a change in actuarial assumptions.

Deferred Inflows of Resources

Deferred inflows of resources represent an acquisition of net position that applies to future periods. The balance of \$644.2 million represents \$634.7 million of future revenues to be recognized from leased assets and \$9.5 million of accumulated OPEB changes in actuarial assumptions and the difference between expected and actual experience used in the other post employment benefit liability.

Net Position

Net position represents the residual interest in the Research Foundation's assets after liabilities are deducted. The Research Foundation's net position at June 30, 2023 and 2022 was \$250.3 million and \$208.3 million, respectively. Net position is summarized into these major categories: net investment in capital assets of \$59.1 million and \$51.5 million, respectively; restricted expendable of \$22.3 million and \$24.4 million, respectively; and unrestricted of \$168.8 million and \$132.3 million, respectively.

Fiscal Year 2022

The Research Foundation's financial position as of the fiscal year ended June 30, 2022 shows an increase in assets, a decrease in liabilities with an overall increase in net position. Assets increased during the fiscal year ended June 30, 2022 by \$39.1 million, as compared to the fiscal year ended June 30, 2021. This increase was due mainly to an increase in cash and equivalents of \$64.2 million offset by reductions of \$3.5 million and \$18.5 million in receivables from affiliates and all other account receivable, respectively. The increase in liabilities of \$14.8 million includes a an increase of accounts payable and accrued liabilities of \$3.7 million and due to the University of \$15.6 million.

Net position increased \$43.7 million due primarily from enhanced clinical services offered through partnerships with other healthcare systems, affiliated healthcare providers, and fixed contract revenues exceeding actual operating expenses.

Statements of Revenues, Expenses, and Changes in Net Position

A condensed version of the Research Foundation's revenues, expenses and changes in net position for the years ended June 30, 2023, 2022, and 2021 (in thousands) is shown below:

	2023	2022	(2021 (Restated)	2023-2022 Change	2022-2021 Change
OPERATING REVENUES						
Clinical services and practice plans	\$ 398,426 \$	398,098	\$	380,121	\$ 328	\$ 17,977
Grants and contracts	128,546	132,023		107,418	(3,477)	24,605
Facilities and administrative cost recoveries	34,378	38,708		32,428	(4,330)	6,280
Other operating revenues	7,741	8,015		6,961	(274)	1,054
TOTAL OPERATING REVENUE	569,091	576,844		526,928	(7,753)	49,916
OPERATING EXPENSES						
Depreciation	8,451	9,043		9,006	(592)	37
Other operating expenses	543,358	546,123		503,646	(2,765)	42,477
TOTAL OPERATING EXPENSE	551,809	555,166		512,652	(3,357)	42,514
NONOPERATING REVENUES (EXPENSES)						
Nonexchange grants and contracts	55,787	84,180		76,083	(28,393)	8,097
Contributions to related entities	(38,451)	(76,269))	(38,097)	37,818	(38,172)
Other nonoperating revenues	7,482	14,255		12,231	(6,773)	2,024
Interest expense	(96)	(130)	,	(161)	34	31
TOTAL NONOPERATING REVENUE/ (EXPENSES)	24,722	22,036		50,056	2,686	(28,020)
INCREASE/(DECREASE) IN NET POSITION	42,004	43,714		64,332	(1,710)	(20,618)
Net position, beginning of year	208,280	164,566		100,234	43,714	64,332
Net position, end of year	\$ 250,284 \$	208,280	\$	164,566	\$ 42,004	\$ 43,714


Operating Revenues

Revenues from operations decreased to \$569.1 million for the year ended June 30, 2023 compared to \$576.8 million for the year ended June 30, 2022. The \$3.5 million decrease in grants and contract and the related decrease of \$4.3 million in facilities and administrative cost recoveries account for the decrease.


Revenue from facilities and administrative cost recoveries were \$34.4 million and \$38.7 million for the years ended June 30, 2023 and 2022, respectively. The Research Foundation compensates the University for a portion of the cost recoveries in support of University expenditures. For the years ended June 30, 2023 and 2022, approximately \$18.3 million and \$20.3 million, respectively, transferred to the University for this purpose.

The following is a graphic illustration of the Research Foundation's operating revenues by major source for the years ended June 30, 2023 and 2022 (in millions):

Operating Revenues Year Ended June 30, 2023




Operating Revenue Trends




Operating Expenses by Functional and Natural Classification


Total operating expenses were \$551.8 million and \$555.2 million for the fiscal years ended June 30, 2023 and 2022, respectively. In fiscal year 2023, operating expenses decreased \$3.4 million. Expenditures for supplies and serviced increased by \$4.3 million while scholarships and fellowships decreased by \$8.3 million. The primary cause of the decrease in scholarship and fellowships relates to HEERF Coronavirus student aid awards received during fiscal year 2022 while HEERF funding was not received during fiscal year 2023.

The following is a graphic illustration of total operating expenses by function for the years ended June 30, 2023 and 2022 (in millions):











The following is a graphic illustration of total operating expenses by natural classification for the years ended June 30, 2023, and 2022 (in millions):

Operating Expenses by Natural Classification Year Ended June 30, 2023



Natural Expense Trends



Nonoperating Revenues (Expenses)

The Research Foundation's total nonoperating revenues of \$24.7 million for fiscal year ended June 30, 2023, was mostly comprised of nonexchange grants and contract revenues of \$55.8 million reduced by transfers to the University of \$38.5 million for support of University operations. Total nonoperating revenues increased by \$2.7 million as compared to fiscal year ended June 30, 2022. The decrease is attributed to nonexchange grants and contract revenues reduction of \$28.4 million, Revenues from the HEERF Coronavirus relief grants are reported in nonexchange grants and contracts and account for the decline in revenues in that category as there were none during fiscal year 2023.

Fiscal Year 2022

For the year ended June 30, 2022, Research Foundation reported \$576.8 million in operating revenues, an increase of \$49.9 million compared to the \$526.9 million reported for the year ended June 30, 2021.

Revenues from clinical services and practice plans were \$398.1 million for fiscal year 2022, an increase of \$18.0 million from the fiscal year ended June 30, 2021. Revenues from grants and contracts were \$132.0 million for the year ended June 30, 2022 as compared to \$107.4 million in revenues reported in the previous year, a \$24.6 million increase. Revenue from facilities and administrative cost recoveries were \$38.7 million million and \$32.4 million million for the years ended June 30, 2022 and 2021 (Restated), respectively.

Total operating expenses were \$555.2 million and \$512.7 million for the fiscal years ended June 30, 2022 and 2021 (Restated), respectively. The increase is attributed to additional operational cost for fully in person activities and increasing salary and wage cost.

Nonoperating revenues and expenses, net, were \$22.0 million and \$50.1 million for the fiscal years ended June 30, 2022 and 2021 (Restated), respectively. The decrease of \$28.0 million is a combination of increased nonexchange grant activity offset by increased contributions to affiliates entities. These increases are connected to the HEERF activity of the Research Foundation and University.

Statements of Cash Flows

The statements of cash flows provide information about the Research Foundation's cash position by reporting the sources and uses of cash during the year. Cash inflows and outflows are categorized as operating, noncapital financing, capital financing and investing activities.

Condensed statements of the Research Foundation's cash flows for the years ended June 30, 2023, 2022, and 2021 (in thousands) are summarized below:

	2023	2021 2023 2022 (Restated)		2023-2022 Change	2022-2021 Change	
CASH (USED)/PROVIDED BY:						
Operating activities	\$ (14,325) \$	16,142	\$	4,024	\$ (30,467)	\$ 12,118
Noncapital financing activities	58,608	51,894		26,072	6,714	25,822
Capital financing activities	(13,651)	(3,797)		(7,525)	(9,854)	3,728
NET (DECREASE)/INCREASE IN CASH EQUIVALENTS	30,632	64,239		22,571	(33,607)	41,668
Cash and cash equivalents, beginning of year	106,781	42,542		19,971	64,239	22,571
CASH AND CASH EQUIVALENTS- END OF YEAR	\$ 137,413 \$	106,781	\$	42,542	\$ 30,632	\$ 64,239

Operating Activities

The Research Foundation's operating activities consumed approximately \$14.3 million of cash during the fiscal year ended June 30, 2023, representing an increase of \$30.5 million compared to the prior year. Reduced grant revenues and reduction of related facilities and administrative cost recovery contributed to this decrease.

Other Activities

The net \$58.6 million cash provided by non-capital and financing activities includes an increase in cash provided by nonexchange grants and contracts of \$55.8 million and \$23.0 million collected on receivables from affiliates offset by payments to the University of \$38.5 million for operating expenses.

Cash used for capital financing activities increased \$9.9 million to \$13.6 million during the fiscal year ended June 30, 2023.

Fiscal Year 2022

The Research Foundation's operating activities provided approximately \$16.1 million of cash during the fiscal year ended June 30, 2022, representing an increase of \$12.1 million compared to the prior year. The increase of cash is the result of the growth in clinical and grant contract activities.

The net \$51.9 million cash provided by non-capital and financing activities relates to \$84.2 million provided by nonexchange grants and contracts and \$5.5 million in gifts, and other activities totaling \$38.5 million, offset by payments to the University of \$76.3 million. In total, cash used for non-capital and related financing activities increased \$25.8 million from the fiscal year ended June 30, 2022.

Cash used for capital financing activities decreased from \$7.5 million to \$3.7 million during the fiscal year ended June 30, 2022 as compared to the fiscal year ended June 30, 2021.

Economic Factors that May Affect the Future

The University is committed to achieving preeminence as a nationally recognized metropolitan research university and as an institution recognized for excellence in education, as well as pioneering in research and scholarly activity. Senior leadership continues to believe the University is financially well-positioned to educate and serve its community through:

- Teaching diverse undergraduate, graduate, and professional students in order to develop engaged citizens, leaders, and scholars,
- · Practicing and applying research, scholarship and creative activity, and
- Providing engaged service and outreach that improve the quality of life for local and global communities.

The following is a brief discussion of economic and other factors that could have an impact on the University in the future:

- Kentucky implemented a performance-funding model in 2017 whereby institutions are incentivized to improve student outcomes based on priorities (metrics) identified by the state. Performance-based funding adds an element of budgetary uncertainty that will impact state funding for the University. The University continues to outpace the sector average in the performance model and received additional state funding of \$14.0 million for fiscal year 2023.
- The projected high school graduate population in the near- and medium-term future is strong through 2026. Institutions focused on first-time, full-time baccalaureate degree-seeking students will be gearing up and recruiting hard during the three year period 2024 to 2026 when graduation rates are expected to peak. However, between years 2027 and 2032, the average graduating class size is expected to decline to levels similar to 2013 which will heighten competition and constrain tuition revenue.
- Continued improved operations of clinical services through engaging in partnerships with Norton Healthcare, Inc. (Norton) and UL Health, Inc.

Requests for Information

This financial report is designed to provide a general overview of the University's finances and to show the University's accountability for the money it receives. Questions about this report and requests for additional financial information should be directed to the Controller, University of Louisville, Louisville, KY 40292.

UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. A Component Unit of the University of Louisville Statements of Net Position as of June 30, 2023 and 2022 (in thousands)

	2023	2022
ASSETS		
Current assets		
Cash and cash equivalents	\$ 137,413	\$ 106,781
Accounts receivable, net	99,025	70,436
Due from affiliate	21,394	30,974
Inventories	514	465
Other assets	332	173
Total current assets	258,678	208,829
Noncurrent assets		
Accounts receivable, net	642,911	654,019
Due from affiliate	13,262	25,625
Other long-term assets	1,251	1,271
Right-to-use asset, net	3,050	5,035
Capital assets, net	58,102	51,475
Total noncurrent assets	718,576	737,425
Total assets	977,254	946,254
DEFERRED OUTFLOWS OF RESOURCES	6,450	5,964
TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES	\$ 983,704	\$ 952,218

UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. A Component Unit of the University of Louisville Statements of Net Position as of June 30, 2023 and 2022 (in thousands)

	2023	2022
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities	37,975	29,817
Due to the University of Louisville	10,394	11,276
Unearned grant revenue	3,727	3,040
Lease payable	1,918	2,236
Total current liabilities	54,014	46,369
Noncurrent liabilities		
Other post-retirement benefits	27,795	30,938
Other long-term liabilities	8	8
Due to the University of Louisville	6,246	4,350
Lease payable	1,153	2,739
Total noncurrent liabilities	35,202	38,035
Total liabilities	89,216	84,404
DEFERRED INFLOWS OF RESOURCES	644,204	659,534
NET POSITION		
Net investment in capital assets	59,149	51,519
Restricted:		
Expendable	22,320	24,422
Unrestricted	168,815	132,339
Total net position	250,284	208,280
TOTAL LIABILITIES, DEFERRED INFLOWS OF RESOURCES AND NET POSITION	\$ 983,704	\$ 952,218

UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. A Component Unit of the University of Louisville Statements of Revenues, Expenses, and Changes in Net Position For Years Ended June 30, 2023 and 2022 (in thousands)

	2023	2022
OPERATING REVENUES		
Clinical services and practice plan, net of contractual allowances of \$75,146 in		
2023 and \$88,182 in 2022	\$ 398,426	\$ 398,098
Federal grants and contracts	97,210	97,217
State and local grants and contracts	16,069	16,370
Nongovernmental grants and contracts	15,267	18,436
Facilities and administrative cost recoveries	34,378	38,708
Sales and services of educational departments	1,523	903
Other operating revenue	6,218	7,112
Total operating revenue	569,091	576,844
OPERATING EXPENSES		
Instruction	98,895	89,044
Research	117,843	123,698
Public service	160,413	159,582
Academic support	91,442	87,312
Institutional support	14,699	14,497
Operation and maintenance of plant	815	3,744
Scholarships and fellowships	59,251	68,246
Depreciation and amortization	8,451	9,043
Total operating expense	551,809	555,166
Operating gain	17,282	21,678
NONOPERATING REVENUES (EXPENSES)		
Gifts	1,044	5,488
Nonexchange grants and contracts	55,787	84,180
Interest expense	(96)	(130
Other nonoperating revenue	6,438	8,767
Net nonoperating revenue	63,173	98,305
Contributions to related entities	(38,451)	(76,269
Total other revenue	24,722	22,036
Increase in net position	42,004	43,714
NET POSITION		
Net position - beginning of year	208,280	164,566
Net position - end of year	\$ 250,284	\$ 208,280

UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. A Component Unit of the University of Louisville Statements of Cash Flows For Years Ended June 30, 2023 and 2022

	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES		
Clinical services	\$ 341,938	\$ 397,851
Grants and contracts	140,233	134,296
Sales and service of educational departments	1,523	903
Payments to suppliers	(189,800)	(192,126)
Payments to employees	(225,806)	(227,457)
Payments for benefits	(58,360)	(70,141)
Payments for scholarships and fellowships	(64,649)	(73,004)
Facilities and administrative cost recoveries	34,378	38,708
Other operating revenue	6,218	7,112
Net cash provided by operating activities	(14,325)	16,142
CASH FLOWS FROM NONCAPITAL FINANCING ACTIVITIES		
Gifts	1,044	5,488
Nonexchange grants and contracts	55,787	84,180
Contributions to related entities	(38,451)	(76,269)
Due to (due from) affiliates	22,958	19,167
Other noncapital financing activities	17,270	19,328
Net cash provided by noncapital financing activities	58,608	51,894
CASH FLOWS FROM CAPITAL AND RELATED FINANCING ACTIVITIES		
Purchases of capital assets	(13,553)	(3,664)
Interest paid	(98)	(133)
Net cash used in capital and related financing activities	(13,651)	(3,797)
Net increase in cash and cash equivalents	30,632	64,239
Cash and cash equivalents - beginning of year	106,781	42,542
Cash and cash equivalents - end of year	\$ 137,413	\$ 106,781

UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. A Component Unit of the University of Louisville Statements of Cash Flows For Years Ended June 30, 2023 and 2022

	2023	2022
RECONCILIATION OF NET OPERATING LOSS TO NET CASH PROVIDED BY OPERATING ACTIVITIES		
Operating gain	\$ 17,282	\$ 21,678
Adjustments to reconcile operating loss to net cash used by operating activities:		
Depreciation and amortization	8,451	9,043
Loss on equipment disposals	459	_
Bad debt expense	2,679	_
Change in assets and liabilities:		
Accounts receivable	(30,996)	8,132
Inventories	(49)	79
Other assets	(159)	506
Other long term assets	21	_
Accounts payable and accrued liabilities	8,162	1,131
Unearned grant revenue	688	(4,042)
Other long-term liabilities	(5,047)	(492)
Deferred outflows of resources	(486)	(526)
Deferred inflows of resources	(15,330)	(19,367)
Net cash provided by (used in) operating activities	\$ (14,325)	\$ 16,142

1. Organizations and Summary of Significant Accounting Policies

The University of Louisville Research Foundation, Inc. (the Research Foundation) is affiliated with the University of Louisville (the University) through common management and substantially the same Board of Directors. The Research Foundation is consolidated into the University's financial statements. The Research Foundation is a separate corporation organized for the purpose of conducting the research, clinical operations, and other sponsored activities of the University. The significant accounting policies followed by the Research Foundation are described below.

a. Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America as prescribed by the Government Accounting Standards Board (GASB). The financial statements of the Research Foundation have been prepared on the accrual basis of accounting. Revenues, expenses, gains, losses, assets, liabilities, and deferred inflows and outflows of resources from exchange and exchange-like transactions are recognized when the exchange transaction takes place, while those from government-mandated nonexchange transactions (principally federal and state grants) are recognized when all applicable eligibility requirements are met. Internal activity and balances are eliminated in preparation of the financial statements unless they relate to services provided and used by affiliates. Operating revenues and expenses include exchange transactions and program-specific, government-mandated nonexchange transactions. Government-mandated nonexchange transactions that are not program specific, investment income and interest on capital asset-related debt and leases are included in nonoperating revenues and expenses. The University first applies restricted net position when an expense or outlay is incurred for purposes for which both restricted and unrestricted net position are available.

The financial statements of the Research Foundation and the University can be found online at the following: http://louisville.edu/finance/controller/univacct/finst-1

b. Cash and Cash Equivalents

The Research Foundation considers all investments with an original maturity of three months or less to be cash equivalents.

c. Accounts Receivable

Accounts receivable consists of clinical and sponsored agreement charges and payment receipts due under lease agreements. Clinical receivables are comprised of patient and insurance charges. Healthcare entities are charged for contracted staff support services. Sponsored agreement receivables relate to sponsored programs that support the Research Foundation. Accounts receivable are recorded net of estimated uncollectible amounts.

d. Inventories

Inventories are stated at the lower of cost or market on a first-in, first-out (FIFO) basis.

e. Capital Assets

Capital assets are stated principally at cost, or estimated acquisition value at date of receipt from donors. Capital assets are depreciated using the straight-line basis over the estimated useful lives of the assets as follows: buildings - 40 years or componentized using 15-50 years, infrastructure - 60 years, land improvements - 40 years, equipment - 3-15 years, leasehold improvements - 20 years and library materials - 10 years. Assets under capital leases are amortized on the straight-line basis over the estimated useful life of the asset, or the lease term, whichever is shorter.

The University has elected to capitalize collections which include art, rare books, photographs, letters, journals, manuscripts and musical instruments. These items are capitalized at cost, or if a gift, at the acquisition value on the date of the gift.

Movable equipment costing \$5,000 and greater and having a useful life greater than one year are capitalized. Renovations to buildings, infrastructure and land improvements, if any, that significantly increase the value or extend the useful life of the structure and are in excess of \$100,000 are capitalized. Necessary and routine repairs and maintenance are charged to operating expense in the year the expense is incurred.

Prior to July 1, 2002 it was the policy of the University to record all capital assets purchased by the Research Foundation as property of the University.

f. Deferred Outflows of Resources

Deferred outflows of resources, are a consumption of net assets that are applicable to a future reporting period and increase net asset position similar to assets. Deferred outflows of resources of \$6.4 million and \$6.0 million for the years ended June 30, 2023 and 2022, respectively, consist of future payments to be made for other post-employment benefits and changes to assumptions used to calculate the future liability.

g. Unearned Grant Revenue

The Research Foundation receives revenues relative to sponsored agreements via grants, contracts, or cooperative agreements. The flow of funds relative to these sponsored agreements is in the form of cost reimbursement or advanced funding.

In the case of cost reimbursement, the Research Foundation incurs costs on behalf of the granting authority and is then reimbursed for such costs pursuant to the terms of the sponsored agreement. Grant revenues are recognized as reimbursable costs are incurred.

In the case of advanced funding, the Research Foundation receives funds prior to incurring costs pursuant to the sponsored agreement, with the stipulation that these funds may have to be returned to the sponsor in the event the project is not completed to the sponsor's satisfaction. These funds, totaling approximately \$3.7 million and \$3.0 million as of June 30, 2023 and 2022, respectively, are recorded as a liability in the Research Foundation's financial statements as unearned grant revenue and recognized as revenue as reimbursable cost are incurred.

h. Compensated Absences

Research Foundation policies permit most employees to accumulate vacation and sick leave benefits that may be realized as paid time off or, in limited circumstances, as a cash payment.

Expense and the related liability are recognized as the vacation or sick benefits are earned, whether the employee is expected to realize the benefit as time off or as cash payment in the event of ending employment. Compensated absence liabilities are computed using the regular pay and termination pay rates in effect at the statement of net position date plus an additional amount for compensation-related payments such as social security and Medicare taxes computed using rates in effect at that date.

i. Deferred inflows of Resources

Deferred inflows of resources are an acquisition of net assets that are applicable to a future reporting period and decrease net position similar to liabilities. Deferred inflows of resources of \$644.2 million and \$659.5 million for the years ended June 30, 2023 and 2022 consist of changes in the other post-employment benefits liability of \$9.5 million and \$7.6 million, respectively, and \$634.7 million and \$651.9 million of future revenues from leasing arrangements and will be amortized during future periods.

j. Net Position

The net position of the Research Foundation is classified in three components.

- a. Net investment in capital assets consist of capital assets and right-to-use assets, net of accumulated depreciation and amortization, and reduced by the outstanding balances of borrowings used to finance the purchase or construction of those assets.
- b. Restricted expendable net position consists of non-capital assets that must be used for a particular purpose as specified by creditors, grantors or donors external to the Research Foundation.
- c. Unrestricted net position consists of the remaining assets less remaining liabilities that do not meet the definition of net investment in capital assets or restricted net position. Although unrestricted net position is not subject to externally imposed stipulations, substantially all of the Research Foundation's unrestricted net position has been designated for various academic programs, research initiatives, and capital projects.

The following table includes detail of the net position balances at June 30, 2023 and 2022 (in thousands):

	2023		2022
Net investment in capital assets	\$ 59	,149 \$	51,519
Restricted expendable for:			
Research	21	046	21,103
Instruction		427	995
Public service		313	751
Academic support		_	5
Institutional support		534	1,568
Unrestricted	168	,815	132,339
Total net position	\$ 250	284 \$	208,280

k. Revenue and Expense Classifications

The Research Foundation has classified its revenues as either operating or nonoperating revenues according to the following criteria:

Operating revenues include activities that have the characteristics of exchange transactions, meaning revenues are received in exchange for goods and services, such as (1) clinical services, (2) grants and contracts, and (3) facilities and administrative cost recoveries. With the exception of interest expense and contributions to related entities, all expense transactions are classified as operating expenses.

Certain significant revenues relied on for fundamental operational support of the university are mandated by GASB requirements to be recorded as nonoperating revenues. Non-operating revenues, meaning revenues received and the university provided no goods or services, include contracts or grants such as Pell and CARES Act, gifts, and investment income.

I. Net Clinical Services Revenue

The Research Foundation has agreements with third-party payers that provide for payments to the Research Foundation at amounts different from its established rates. Net clinical services revenue is reported at the estimated net realizable amounts from patients, third-party payers and others for the services rendered and includes estimated retroactive revenue adjustments and a provision for uncollectible accounts. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered and such estimated amounts are revised in future periods as adjustments become known.

Support funded by grants is recognized as the Research Foundation performs the contracted services or incurs outlays eligible for reimbursement under the grant agreements. Grant activities and outlays are subject to audit and acceptance by the granting agency and, as a result of such audit, adjustments could be made.

m. Tax Status

As an affiliate of a state institution of higher education, the income of the Research Foundation is generally exempt from federal and state income taxes under Section 115(a) of the Internal Revenue Code and a similar provision of state law. However, the Research Foundation is subject to federal income tax on any unrelated business income.

n. Use of Estimates

The preparation of the financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

o. Reclassifications

Certain 2022 amounts have been reclassified to conform to the 2023 presentation. The reclassifications more accurately represent revenue and expense activities in the categories presented on the statement of revenues, expense and changes in net position. These reclassifications had no effect on the change in net position.

p. Recent Accounting Pronouncements and Restatement

GASB Statement No. 94, *Public-Private and Public-Public Partnerships and Availability Payment Arrangements*, and GASB Statement No. 96, *Subscription Based Information Technology Arrangements* were applicable for adoption as of June 30, 2023. Contracts and agreements of the Research Foundation were reviewed to determine the applicability of the pronouncements and none were deemed applicable.

The following statements will be implemented in future reporting periods:

GASB Statement No. 101, *Compensated Absences*. The statement updates the recognition and measurement guidance for compensated absences and amends certain previously required disclosures. The Association has not yet adopted the standard and is evaluating the impact it may have on its financial statements.

2. Cash and Cash Equivalents

The Research Foundation maintains various deposits. Custodial credit risk for deposits is the risk that in the event of a bank failure, the Research Foundation's deposits or collateral securities may not be returned to it. For administrative convenience, cash balances of the Research Foundation are included in bank accounts maintained by the University. Details of accounting transactions affecting cash are maintained in such a manner as to ensure an appropriate segregation of amounts maintained by each entity.

The University currently uses commercial banks and the Commonwealth of Kentucky (the Commonwealth) as its depositories. Deposits with commercial banks are covered up to the limits federal depository insurance or collateral held by the bank in the University's name. At the Commonwealth, the University's accounts are pooled with other agencies of the Commonwealth. These Commonwealth-pooled deposits are substantially covered by federal depository insurance or by collateral held by the Commonwealth in the Commonwealth's name. The Research Foundation does not have a formal policy addressing custodial credit risk.

3. Transactions with Related Entities

a. Contributions with Related Entities

The University provides certain facilities and administrative services to the Research Foundation for a share of the facilities and administrative cost recoveries. The current agreement provides for a transfer of 80%, after certain deductions, of the cost recoveries realized. Transfers from the Research Foundation to the University for their portion of cost recoveries totaled \$18.3 million and \$20.3 million for the years ended June 30, 2023 and 2022, respectively.

During the fiscal year ended June 30, 2023 research and operational support provided to the University from the Research Foundation totaled \$7.1 million. During the fiscal year ended June 30, 2022 the Research Foundation received \$24.0 million for research and operational support, which included approximately \$8.2 million in CARES and HEERF funding.

The Research Foundation transferred \$14.8 million and \$21.6 million of the academic and programmatic support payments received from UL Health to the University during the years ended June 30, 2023 and 2022.

The Research Foundation transferred \$3.2 million and \$7.3 million related to capital projects and debt service payments during each of the fiscal years ended June 30, 2023 and 2022, respectively to the University. These transfers relate to certain capital projects, which are financed by the University.

For each of the years ended June 30, 2023 and 2022, the Research Foundation was the recipient of \$5.0 million and \$4.7 million, respectively, from related entities to assist in funding cost share required by certain sponsored programs and grants.

b. Receivables With Related Entities

The Research Foundation received a \$5.9 million unsecured, non-interest bearing note from University of Louisville Physicians, Inc. (ULP), an affiliate entity, for past due fees owed to the Research Foundation. The outstanding note balance was \$1.6 million and \$2.4 million as of June 30, 2023 and 2022, respectively.

The Research Foundation has receivables from ULP due through the normal course of business and reflected in loans, accounts and contributions receivable, net in the Statements of Net Position. As of June 30, 2023 and 2022 receivables of \$97 thousand and \$13 thousand were due, respectively.

In relation to the academic and programmatic support provided by UL Health, Inc. to the Research Foundation, UL Health, Inc.'s Board of Directors approved additional academic mission support of \$7.9 million and \$22.3 million for the years ended June 30, 2023 and 2022. During fiscal year 2023, the Research Foundation received payments of \$27.9 million related to the agreement with UL Health. As of June 30, 2023, the remaining balance due is \$33.0 million of which \$20.5 million is reported in current due from affiliates and \$12.5 million is reported in noncurrent due from affiliates.

The Research Foundation has receivables from UL Health due through the normal course of business and reflected in loans, accounts and contributions receivable, net in the Statements of Net Position. As of June 30, 2023 and 2022, receivables of \$13.3 million and \$8.4 million were due, respectively.

4. Accounts Receivable, net

Accounts receivable, net as of June 30, 2023 and 2022, are summarized as follows (in thousands):

				2023		
	Gross	Receivable		Allowance	Ne	t Receivable
Patient care	\$	86,703	\$	(22,416)	\$	64,287
Sponsored agreements		27,559		(3,067)		24,492
Lease Receivables		653,157		_		653,157
Total	\$	767,419	\$	(25,483)	\$	741,936
Current portion						99,025
Noncurrent portion						642,911
				2022		
	Gross	s Receivable		Allowance	Ne	t Receivable
Patient care	\$	43,396	\$	(18,425)	\$	24,971
Sponsored agreements		37,255		(1,763)		35,492
Lease Receivables		663,992	\$	_		663,992
Total	\$	744,643	\$	(20,188)	\$	724,455
Current portion			<u> </u>			70,436
Noncurrent portion						654,019

5. Capital and Intangible Assets, net

Capital assets and intangible assets as of June 30, 2023 and 2022 are summarized as follows (in thousands):

			2023		
	Beginning Balance	Additions	Retirements	Transfers	Ending Balance
Cost - Nondepreciable					
Land	\$ 351	\$ -	\$ -	\$ -	\$ 351
Construction in progress	602	6,406	(234)	_	6,774
Subtotal	953	6,406	(234)	-	7,125
Cost - Depreciable					
Buildings	71,002	116	_	_	71,118
Infrastructure	929	_	_	_	929
Land improvements	237	_	_	_	237
Equipment	102,044	6,673	(1,897)	_	106,820
Leasehold improvements	818	_	_	_	818
Library materials	62	_	(2)	_	60
Right-to-use asset - leases	9,631	358	_	_	9,989
Subtotal	184,723	7,147	(1,899)	_	189,971
Total capital and intangible assets, cost	185,676	13,553	(2,133)	-	197,096
Accumulated depreciation and amortization					
Buildings	34,028	1,428	_	_	35,456
Infrastructure	132	16	_	_	148
Land improvements	76	6	_	_	82
Equipment	89,535	4,650	(1,673)	_	92,512
Leasehold improvements	749	6	_	_	755
Library materials	50	2	_	-	52
Right-to-use asset - leases	4,596	2,343		_	6,939
Total accumulated depreciation and amortization	129,166	8,451	(1,673)	_	135,944
Capital and intangible assets, net	\$ 56,510	\$ 5,102	\$ (460)	\$ –	\$ 61,152

			2022		
	Beginning Balance	Additions	Retirements	Transfers	Ending Balance
Cost - Nondepreciable					
Land	\$ 351	\$ -	\$ - 9	\$ -	\$ 351
Construction in progress	_	602	_	_	602
Subtotal	351	602	-	_	953
Cost - Depreciable					
Buildings	70,941	61	_	_	71,002
Infrastructure	929	_	_	_	929
Land improvements	237	_	_	_	237
Equipment	99,090	3,369	(415)	_	102,044
Leasehold improvements	818	_	_	_	818
Library materials	62	_	_	_	62
Right-to-use asset	7,575	2,056	_	_	9,631
Subtotal	179,652	5,486	(415)	_	184,723
Total capital and intangible assets, cost	180,003	6,088	(415)		185,676
Accumulated depreciation and amortization					
Buildings	31,315	2,713	_	_	34,028
Infrastructure	117	15	_	_	132
Land improvements	70	6	_	_	76
Equipment	85,941	4,009	(415)	_	89,535
Leasehold improvements	743	6	_	_	749
Library materials	49	1	_	_	50
Right-to-use asset	2,303	2,293	_	_	4,596
Total accumulated depreciation and amortization	120,538	9,043	(415)	_	129,166
Capital and intangible assets, net	\$ 59,465	\$ (2,955)	\$ - :	\$ <u> </u>	\$ 56,510

6. Leases

a. Lessee Arrangements

The Research Foundation leases operating and office facilities for various terms under long-term, non-cancelable lease agreements. The leases expire at various dates through 2033 and provide for renewal options ranging from one year to fifty years. The Research Foundation records right-to-use assets and lease liabilities based on the present value of expected payments over the lease term of the respective leases. The expected payments are discounted using the interest rate charged on the lease, if available, or are otherwise discounted using the Association's incremental borrowing rate. Variable payments are excluded from the valuations unless they are fixed in substance. Those variable payments are recognized as outflows of resources in the periods in which the obligation for those payments is incurred. Certain facility leases provide for increases in future minimum annual rental payments based on defined increases in the Consumer Price Index, subject to certain minimum increases. The Research Foundation does not have any leases subject to a residual value guarantee. Right-to-use assets acquired through outstanding leases are buildings.

See Note 5, Capital Assets for balances of right-to-use assets and associated accumulated amortization. See Note 7 Other Liabilities for balances of lease liabilities.

Total future minimum lease payments to be made under lease agreements are as follows (in thousands):

For the years ending June 30,	Principal	Interest
2024	1,918	3 50
2025	443	3 24
2026	464	12
2027	65	5 5
2028	44	4
2029-2033	137	5
Total future payments	\$ 3,071	1 \$ 100

b. Lessor Arrangements

The Research Foundation holds the leases of the University hospitals to an external affiliated party. The leases expire at various dates through 2060 and have renewals for five-year periods. The Research Foundation records lease receivables as deferred inflows of resources based on the present value of expected receipts over the term of the respective leases. The expected receipts are discounted using the interest rate charged on the lease or the Research Foundation's incremental borrowing rate. Variable payments are excluded from the valuations unless they are fixed in substance. During the years ended June 30, 2023 and 2022, the Research Foundation recognized revenues relating to these lease arrangements totaling \$26.7 million.

7. Other Liabilities

Other liabilities of the Research Foundation consisted of the following at June 30, 2023 and 2022 (in thousands):

					20	23				
	ginning alance	,	Additions	R	eductions		Ending Balance	Current Portion	1	Noncurrent Portion
Leases payable	\$ 4,975	\$	361	\$	(2,265)	\$	3,071	\$ 1,918	\$	1,153
Other long-term liabilities	8		_		_		8	_		8
Total	\$ 4,983	\$	361	\$	(2,265)	\$	3,079	\$ 1,918	\$	1,161

					20	22			
	ginning alance	A	Additions	R	eductions		Ending Balance	Current Portion	oncurrent Portion
Leases payable	\$ 5,099	\$	1,838	\$	(1,962)	\$	4,975	\$ 2,236	\$ 2,739
Other long-term liabilities	22		_		(14)		8	_	8
Total	\$ 5,121	\$	1,838	\$	(1,976)	\$	4,983	\$ 2,236	\$ 2,747

8. Revenues from Clinical Services, Contractual Services and Practice Plans

a. Clinics and Laboratories

The University's Health Science Center operates various clinics, which generate revenues from the treatment of patients, as well as laboratory services. Net revenues associated with the operations of these clinics totaled approximately \$129.2 million and \$105.8 million for the years ended June 30, 2023 and 2022, respectively.

b. UL Health, Inc.

During the fiscal year ending June 30, 2020 UMC became wholly owned by UL Health, Inc. UL Health, Inc. consolidated the management of existing hospital facilities and facilities obtained in acquisition with operations of UMC and ULP to optimize operations and management. UL Health, Inc.'s operating agreement with the University states that profitable operations in excess of budget will be shared equally with the university. The profit share contribution was \$7.9 million and \$22.3 million for the years ended June 30, 2023 and 2022, respectively.

The University has an academic affiliation agreement with UL Health for the purpose of advancing the University's academic, education and research missions, providing quality patient care regardless of ability to pay and assurance that state-of-the-art facilities will be available for providing healthcare to patients. University employees, residents and students provide medical care utilizing UL Health run facilities, in return, UL Health receives revenues for the services provided. UL Health provides support to the University through annual funding for salaries, benefits and insurance coverage, annual academic support and annual departmental/administrative support pursuant to the terms of the master support and services agreement. For the years ending June 30, 2023 and 2022, support totaling approximately \$146.2 million and \$150.1 million, respectively, was received under these agreements.

c. Norton Healthcare

The University entered into an agreement with Norton Hospitals, Inc. and Norton Children's Medical Group, LLC (collectively "NCMG") to transition the ownership and operation of the pediatric clinical practice and amend and restate certain other aspects of the pediatric academic affiliation in order align teaching, research and patient care between the parties. As of March 1, 2020, NCMG assumed all operational responsibilities for pediatric clinical activities.

The Clinical Affiliation and Academic Affiliation Agreements between the University and NCMG provides for certain payments to the university for academic and departmental support of teaching and research.

The Research Foundation received total support of \$86.1 million and \$84.5 million related academic, departmental and research support for June 30, 2023 and 2022, respectively. Norton made additional payments to the Research Foundation for professional services provided by clinical providers of \$1.4 million and \$2.3 million for the years ending June 30, 2023 and 2022, respectively.

d. Other Clinical Revenues

The Research Foundation works with other area hospitals by providing support services, such as residents and other staff. Revenues associated with these activities totaled approximately \$24.9 million and \$33.1 million for the years ended June 30, 2023 and 2022, respectively.

9. Natural Classification

Operating expenses by natural classification for the years ended June 30, 2023 and 2022 were approximately (in thousands):

					2023			
	s	alary and wages	ا	Employee benefits	cholarships and ellowships	Sı	pplies and other	Total
Instruction	\$	69,661	\$	16,595	\$ 2,535	\$	10,104	\$ 98,895
Research		58,212		15,222	3,039		41,370	117,843
Public service		44,965		11,250	314		103,884	160,413
Academic support		43,224		9,580	905		37,733	91,442
Institutional support		7,814		306	_		6,579	14,699
Operation and maintenance of plant		665		262	_		(112)	815
Scholarships and fellowships		1,265		70	57,881		35	59,251
Depreciation and amortization		-		-	_		-	8,451
Total	\$	225,806	\$	53,285	\$ 64,674	\$	199,593	\$ 551,809

					2022			
	S	alary and wages	ı	Employee benefits	cholarships and ellowships	Sı	upplies and other	Total
Instruction	\$	64,530	\$	15,148	\$ 1,876	\$	7,490	\$ 89,044
Research		63,576		15,893	2,849		41,380	123,698
Public service		46,322		11,115	241		101,904	159,582
Academic support		41,995		9,195	734		35,388	87,312
Institutional support		8,260		(145)	(53)		6,435	14,497
Operation and maintenance of plant		835		238	_		2,671	3,744
Scholarships and fellowships		882		6	67,357		1	68,246
Depreciation and amortization		_		_	_		_	9,043
Total	\$	226,400	\$	51,450	\$ 73,004	\$	195,269	\$ 555,166

10. Funding from Higher Education Relief Funds

The Federal Government passed the Coronavirus Aid, Relief, and Economic Security (CARES) Act on March 27, 2020 the Coronavirus Response and Relief Supplemental Appropriations Act of 2021 on December 27, 2020 and the American Rescue Plan Act of 2021 on March 11, 2021 all of which included funding for the Higher Education Emergency Relief Fund (HEERF). These funds were awarded to institutions of higher education in multiple allotments. The University received funding in two allotments: institutional aid to provide support for pivoting instruction to online delivery, and a student portion to provide emergency financial aid grants to students. The University received allocations totaling \$31.3 million for financial aid grants and \$39.2 million for institutional aid. These revenues are included in the Nonoperating revenue (expenses) and expenses are reported in institutional and scholarship operating expense section of the Statements of Revenues, Expenses, and Changes in Net Position. All relief funds were utilized as of June 30, 2022.

11. Retirement Plan

Full and benefit eligible part-time employees can participate in the university of Louisville 403(b) Retirement Plan (Plan) immediately upon hire. The University contributes 7.5% of an eligible employee's base salary regardless of an employee's participation in the plan. Additionally, the University matches employee contributions up to 2.5% of base pay. Both the University contribution and match are subject to eligibility requirements of twelve-months of consecutive service and attainment age 21. The Plan requires three years of continuous service for employees to vest in the University contributions.

The Research Foundation recorded expenses related to the defined contribution plan of approximately \$13.8 million and \$8.1 million during the years ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and 2022, the Research Foundation had no outstanding liability related to the Retirement Plan.

12. Postemployment Healthcare Benefits

a. Plan Description

University personnel are eligible for post employment healthcare benefits as described in The University of Louisville Group Health Plan (Plan), administered by the University. The Plan is a single-employer plan and the University's Board of Trustees determines the eligibility requirements related to the Plan. The Plan does not issue stand-alone financial reports and is not included in the report of any entity.

To be eligible for the Plan, a retired employee must be the earlier of the attainment of age 60 with seven years of service in eligible faculty or staff status, or the date that the sum of the employee's age and years of regular service of not less than 80% full-time equivalent at the University equals or exceeds 75.

The following employees were covered by the benefit terms as of July 1, 2023 and 2022:

	2023	2022
Retirees and beneficiaries	1,916	1,586
Active plan members	4,446	4,701
Total	6,362	6,287

b. Funding Policy

The Plan is funded on a pay-as-you-go basis. The contribution requirements of the contributing members are determined by the University's management on an annual basis. During the years ended June 30, 2023 and 2022, the University contributed approximately \$3.9 million and \$3.7 million to the Plan, approximately 80% of total premiums. Retired Plan members under age 65 receiving benefits contributed approximately \$958 thousand and \$924 thousand, approximately 20% of total premiums. Health plan rates remained unchanged for the year ended June 30, 2023. Retired Plan members made monthly contributions according to the rate schedule below.

	PPO	EPO	PCA High	PCA Low		
Employee	\$ 416	\$ 445	\$ 353	\$ 291		
Employee and Spouse	\$ 1,000	\$ 1,069	\$ 847	\$ 698		

Medicare-eligible retirees receive a monthly benefit of \$108 per individual covered. For the years ended June 30, 2023 and 2022, the University contributed \$2.5 million and \$2.2 million for Medicare-eligible retirees, respectively.

c. Annual Other Post Employment Benefit (OPEB) Cost and Net OPEB Obligation

The University's total OPEB liability was measured by an actuarial valuation as of June 30, 2022. The total OPEB liability in the actuarial valuation was determined using the following actuarial assumptions, applied to all periods included in the measurement, unless otherwise specified.

Inflation	2.25%
Salary Increases	5.00%, average
Investment rate of return	NA
Healthcare cost trend rates	7.0% for 2021, decreasing 0%-0.25% per year to an ultimate rate of 4.25% for 2038 and later years

The investment rate of return is shown as not applicable (NA) since the University contributes only the amount necessary to pay current benefits. The discount rate is 3.69% as of the Measurement Date, 1.92% as of the beginning of the Measurement Period.

Changes in total reported liability for postemployment benefits obligations for the year ended June 30, 2023 and 2022 are summarized below (in thousands):

	2023	2022
Balance, beginning year	\$ 85,940 \$	80,238
Changes for the year:		
Service cost	2,983	2,795
Interest	1,642	1,956
Differences between expected and actual experience	4,771	(458)
Changes of assumptions	(12,131)	4,967
Benefit payments	(3,790)	(3,558)
Net changes	(6,525)	5,702
Balance, end year	\$ 79,415 \$	85,940

The following reflects the sensitivity of the net OPEB liability if it were calculated using a discount rate that is one-percentage-point lower or one-percentage-point higher than the current discount rate (in thousands):

		2023		2022							
	Decrease (2.69)%	oiscount e (3.69)%	19	1% Increase (4.69)%		6 Decrease (0.92)%	Discount Rate (1.92)%		1% Increase (2.92)%		
Net OPEB liability	\$ 88,490	\$ 79,415	\$	71,721	\$	96,719	\$	85,940	\$	76,935	

The following reflects the sensitivity of the net OPEB liability if it were calculated using a healthcare cost trend rate that is one- percentage-point lower or one-percentage-point higher than current health care trend rate (in thousands):

			;	2023				2022		
	1%	Decrease (6.0)%	Co	althcare st Trend es (7.0)%	19	% Increase (8.0)%	Decrease (0.92)%	oiscount te (1.92)%	19	% Increase (2.92)%
Net OPEB liability	\$	76,079	\$	79,415	\$	83,296	\$ 96,719	\$ 85,940	\$	76,935

For the year ended June 30, 2023 the University recognized OPEB expense of \$1.5 million. At June 30, 2023, the University reported deferred outflows of resources and deferred inflows of resources related to OPEB from the following sources:

	Deferred Outflows of Resources	Deferred Inflows of Resources			
Differences between expected and actual experience	\$ 4,972	\$	2,858		
Changes of assumptions	9,520		24,187		
Contributions made in fiscal year ending 6/30/2023 after the measurement date of 6/30/2022	3,936		<u> </u>		
Total	\$ 18,428	\$	27,045		

The amount reported as contributions after the measurement date included in deferred outflows will be recognized as benefit payments during the following fiscal year.

Amounts reported as differences between expected and actual experience and changes in assumptions included under deferred inflows of resources will be recognized in OPEB expense during the following years as presented below (in thousands):

	Year ended June 30:	
	2024	\$ (3,100)
	2025	(3,100)
	2026	(2,683)
	2027	(2,583)
	2028	(334)
	Thereafter	(753)
Total		\$ (12,553)

d. Funded Status and Funding Progress

As of June 30, 2022, the most recent actuarial valuation date, the plan was 0% funded. The unfunded OPEB liability for benefits was \$79.4 million and \$85.9 million and there were no assets, resulting in an unfunded net OPEB liability of \$79.4 million and \$85.9 million as of June 30, 2023 and 2022, respectively. The covered payroll (annual payroll of active employees covered by the plan) was \$445.2 million and \$434.9 million, and the ratio of the unfunded net OPEB liability to the covered payroll was 18% and 20%, for the years ended June 30, 2023 and 2022, respectively.

Actuarial valuations of an ongoing plan involve estimates of the value of reported amounts and assumptions about the probability of occurrence of events far into the future. Examples include assumptions about future employment, mortality, and the healthcare cost trends. Amounts determined regarding the funded status of the plan and the annual required contributions of the employer are subject to continual revision as actual results are compared with past expectations and new estimates about the future.

e. Actuarial Methods and Assumptions

Projections of benefits for financial reporting purposes are based on the substantive plan (the plan as understood by the employer and the plan members) and include the types of benefits provided at the time of each valuation and the historical pattern of sharing of benefit costs between the employer and plan members to that point. The actuarial methods and assumptions used include techniques that are designed to reduce the effects of short-term volatility in actuarial accrued liabilities and the actuarial value of assets, consistent with the long-term perspective of the calculations.

13. Commitments and Contingencies

a. Commitments

At June 30, 2023 and 2022, respectively, the Research Foundation had approximately \$12.3 million and \$441 thousand in encumbrance's outstanding related mainly to operational expenses for future expenditures.

b. Litigation

The University has been named as defendant in several lawsuits, including several actions initiated by patients involving alleged malpractice. It is the opinion of management and its legal counsel, based in part on the doctrine of sovereign immunity, commercial insurance coverages and other statutory provisions, that the ultimate outcome of litigation will not have a material effect on the future operations or financial position of the University or the Research Foundation beyond the amounts already provided.

c. Government Grants

The Research Foundation is currently participating in numerous grants from various departments and agencies of the federal and state governments. The expenditure of grant proceeds must be for allowable and eligible purposes. Single audits and audits by the granting department or agency may result in requests for reimbursement of unused grant proceeds or disallowed expenditures. Upon notification of final approval by the granting department or agency, the grants are considered closed.

REQUIRED SUPPLEMENTARY INFORMATION Schedule of Changes in Total OPEB Liability and Related Ratios For the Fiscal Year Ending (in thousands)

	6/30/2023		6/30/2022		6/30/2021		6/30/2020		6/30/2019		6/30/2018	
Total OPEB liability												
Service Cost	\$	2,983	\$	2,795	\$	2,538	\$	2,437	\$	4,630	\$	5,203
Interest		1,642		1,956		2,318		2,497		3,296		2,728
Difference between expected and actual experience		4,771		(458)		(1,687)		1,923		(1,718)		(2,608)
Changes of assumption		(12,131)		4,967		5,757		5,488		(27,504)		(5,495)
Benefit payments		(3,790)		(3,558)		(2,927)		(2,836)		(2,817)		(3,007)
Net change in OPEB Liability	\$	(6,525)	\$	5,702	\$	5,999	\$	9,509	\$	(24,113)	\$	(3,179)
OPEB liability - beginning of year		85,940		80,238		74,239		64,730		88,843		92,022
OPEB liability - end of year	\$	79,415	\$	85,940	\$	80,238	\$	74,239	\$	64,730	\$	88,843
Covered employee payroll	\$	445,201	\$	434,864	\$	490,221	\$	493,893	\$	450,332	\$	445,356
Total OPEB liability as a percentage of covered employee payroll		17.84%		19.76%		76% 16.37%		15.03 %	5.03 % 14.37 %		% 19.95 %	

This schedule is to be built prospectively. Until a full 10-year trend is compiled, the schedule will show information for those years for which data is available.



There is no implied consent for any use, publication, republication or transmission of material registered to UofL.